Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.41 |
| ▸ | FES | P07332 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286379 | 0.91 | EGFR (0.57) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3280387 | 0.89 | SYK (0.58) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3280304 | 0.85 | KDR (0.43) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3279464 | 0.84 | PDGFRB (0.45) | PDGFRBPDGFRASYKFLT3 | |
| SCHEMBL3279915 | 0.83 | PDGFRB (0.41) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3281003 | 0.82 | PDGFRB (0.40) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3279022 | 0.79 | KMT2A (0.44) | PDGFRBPDGFRA | |
| SCHEMBL3286300 | 0.79 | IKBKB (0.43) | PDGFRBPDGFRA | |
| SCHEMBL3280195 | 0.79 | PDGFRB (0.38) | PDGFRBPDGFRASYKEGFRFGFR1 | |
| SCHEMBL3279674 | 0.78 | FLT3 (0.48) | SYKEGFRFGFR4FLT3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | PDGFRB 388/4885PDGFRA 454/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.